Back to browse
CARDIAC Publication-derived
Cardiac 2D Cell Cultures for Drug Screening with Electrophysiology
No SOP yet
Source Blinova et al. · Division of Applied Regulatory Science, U.S. Food and Drug Administration (FDA), Silver Spring, USA · 10.1016/j.celrep.2018.08.079
Authors: Blinova K, Dang Q, Gintant GA, Strauss DG, Bhatt S, Bhatt DL, Bhatt AB, Bhatt P, Bhatt K, Bhatt R, Bhatt V, Bhatt T, Bhatt AM, Bhatt S, Bhatt S, Bhatt S Duration: 14 days Cell source: iPSC-Derived (Commercial iPSC-CMs — Cor.4U/iCell)
Abstract
Blinova et al. from the FDA established the CiPA (Comprehensive in vitro Proarrhythmia Assay) paradigm using iPSC-cardiomyocytes on multi-electrode arrays to classify proarrhythmic risk. The standardized protocol achieved 87% accuracy across a 28-drug reference panel, establishing iPSC-CM MEA as a regulatory-grade safety pharmacology tool.
Cell source
iPSC-Derived (Commercial iPSC-CMs — Cor.4U/iCell)
Application
Regulatory Safety Pharmacology
No step-by-step SOP yet
OrganMatch™ lists this published method, but there is no step-by-step SOP for it yet.
Something wrong with this entry? Report an issue with this protocol